Original Article
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastrointest Endosc. Sep 16, 2014; 6(9): 419-431
Published online Sep 16, 2014. doi: 10.4253/wjge.v6.i9.419
Table 3 Implantable gastric stimulator Transcend®: Studies summary
Ref.Type of researchSample size, (enrolled/completed)Mean age (yr)Mean weight, (kg)/mean BMI (kg/m2)Follow-up (mo)Lifestyle change (required/advice given)Baroscreen®
Korner et al[28], 2011Randomized + D, PC (SHAPE)13/1348.8113.1/40.624Y/YY
Shikora et al[21], 2009Randomized + P, D, M, PC (SHAPE)190/18043.9NR/4112Y/YY
Hoeller et al[73], 2006Non-randomized8/748.1112.5/41.323NR/NRN
Champion et al[29], 2006Non-randomized + O24/214392/336Y/YY
Miller et al[30], 2006Non-randomized + P, M (LOSS trial)91/2541116/4124N/YY
Shikora et al[20], 2005randomized + D, PC103/3440129/4629NR/NRN
(O-01 trial)
Shikora et al[20], 2005Non- randomized + O, M (DIGEST)30/2339NR/4224Y/YN1
Cigaina et al[32], 2004Non- randomized65/NR39.4 ± 3.4132.7 ± 27.3/46.9 ± 7.07962Y/YNR1
Favretti et al[74], 2004Non- randomized20/2040115/40.910N/YNR
De Luca et al[36], 2004Non- randomized + P (LOSS trial)69/2041115/4115NR/NRNR
Cigaina et al[75], 2003Non- randomized11/1139.4 ± 3.4121.7 ± 5.1/46.0 ± 2.58N/YNR
McCallum et al[35], 2002randomized + D103/NR40NR/4612NR/NRNR
D'Argent et al[76], 2002Non- randomized + P, O12/NR40.6122.2/42.79NR/NRNR